Drug Profile


Alternative Names: ACE-011; RAP-011

Latest Information Update: 21 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Acceleron Pharma
  • Developer Acceleron Pharma; Celgene Corporation; Indiana University; North Shore-Long Island Jewish Health System; University of Texas M. D. Anderson Cancer Center
  • Class Osteoporosis therapies; Recombinant fusion proteins
  • Mechanism of Action Activin inhibitors; Bone development stimulants; Haemoglobin stimulants; Osteoblast inhibitors; Osteoclast stimulants; Osteogenesis stimulants; Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Beta-thalassaemia; Anaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia; Beta-thalassaemia; Myelofibrosis; Renal osteodystrophy; Vascular calcification
  • Phase I/II Diamond-Blackfan syndrome
  • Preclinical Pulmonary hypertension
  • No development reported Cancer metastases; Chemotherapy-induced anaemia; Postmenopausal osteoporosis; Sickle cell anaemia

Most Recent Events

  • 19 Sep 2017 Acceleron Pharma amends collaboration and development agreement with Celgene to provide the former with global rights to develop and commercialise sotatercept for Pulmonary hypertension
  • 19 Sep 2017 Preclinical trials in Pulmonary hypertension in USA (Parenteral) before September 2017
  • 19 Sep 2017 Acceleron Pharma plans a phase II trial for Pulmonary hypertension in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top